Gt biopharma, inc. announces 1-for-30 reverse stock split

Brisbane, california, feb. 01, 2024 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp) (the “company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. the reverse stock split will become effective at 5:00 p.m. eastern time, on february 2, 2024. the company's common stock will continue to be traded on the nasdaq capital market under the symbol “gtbp” and will begin trading on a post-split basis at the market open on february 5, 2024. the cusip number for the common stock following the reverse stock split will be 36254l 308. the reverse stock split is part of the company's plan to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the nasdaq capital market.
GTBP Ratings Summary
GTBP Quant Ranking